Developer docs
API playgroundTry for free, no card

Search company profiles

BioLoomics

Full company profile

uuid0002hzq

Namestring
BioLoomics
Legal namestring
BioLoomics, Inc.
Websiteurl
bioloomics.com
Company typeenum
Private
Founded yearint
2019
Short descriptiontext

BioLoomics is a Boulder, Colorado preclinical biotechnology company that uses a directed evolution platform in human cells to develop enhanced antibody-drug conjugates (Super-ADCs) for cancer therapeutics, monetizing through co-development partnerships and licensing with large pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, cancer therapeutics development, directed evolution platform, preclinical antibody engineering, oncology biotech research
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biotechnology / Antibody Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Co-development Partnerships
TypeLicensing Royalties
Description

BioLoomics plans to form strategic partnerships with large pharmaceutical companies for co-development of Super-ADC therapeutics. Revenue would come from development milestone payments, licensing fees, and potential royalty arrangements.

bioloomics.com
2Pre-clinical Asset Development
TypeLicensing Royalties
Description

Developing pre-clinical assets internally with intent to out-license or partner with pharmaceutical companies for clinical development and commercialization.

bioloomics.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Super-ADCs
Description

A proprietary technology platform that enhances antibody-drug conjugates (ADCs) using oligomerizing membrane binding peptides to improve tumor cell uptake and reduce off-target toxicities.

bioloomics.com
Core offering1 text field

BioLoomics develops next-generation antibody-drug conjugates (Super-ADCs) using a proprietary directed evolution platform that engineers antibodies in human cells. The Super-ADCs incorporate oligomerizing membrane binding peptides that enhance tumor cell uptake and payload delivery, addressing the limitation of traditional ADCs that deliver less than 1% of chemotherapy payload to tumors. The company develops pre-clinical assets internally and intends to out-license or co-develop them with large pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Traditional ADCs deliver less than 1% of chemotherapy payload to tumors; Super-ADCs have potential to significantly improve this ratio by enhancing payload delivery through membrane binding peptides
Product and service3 records
1Super-ADCs (Super Antibody-Drug Conjugates)
CategoryCore product / Antibody-Drug Conjugate therapeutics platform
Description

Next-generation antibody-drug conjugates that incorporate an oligomerizing membrane binding peptide to improve tumor cell uptake. Super-ADCs address the limitation of traditional ADCs that deliver less than 1% of chemotherapy payload to tumors, enhancing payload delivery and reducing off-target toxicities for cancer therapeutics. Targeted at large pharmaceutical companies for co-development partnerships.

2Directed Evolution Platform
CategoryCore platform / Antibody engineering technology
Description

A proprietary platform for directed evolution of target degrading antibodies using human cells, enabling the design of antibodies with enhanced functionalities for improved cancer therapeutics. The platform is the technological foundation underlying the company's Super-ADC program and pre-clinical pipeline.

3Pre-clinical ADC Asset Development
CategoryResearch and development / Pre-clinical assets
Description

Internal development of pre-clinical antibody-drug conjugate assets for cancer therapeutics using BioLoomics' proprietary directed evolution platform. Assets are developed with the intent to out-license or co-develop with pharmaceutical partners for clinical development and commercialization.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Large Pharmaceutical Companies
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioLoomics plans to form strategic partnerships with large pharmaceutical companies to develop pre-clinical assets and advance Super-ADC technology for therapeutic solutions. Partnerships aim to improve therapeutic index of existing assets and enable lower potency payloads in ADC field.

bioloomics.com
Peers10 records
TypeDirect peer
Description

Clinical-stage ADC developer with proprietary conjugation and payload platforms (e.g., Dolasynthen, Immunosynthen). Directly comparable to BioLoomics as an ADC-platform company pursuing next-generation antibody conjugate technologies for oncology.

TypeDirect peer
Description

Developer of masked Probody therapeutics that are activated in the tumor microenvironment. Comparable to BioLoomics as a next-generation ADC/antibody platform company improving tumor selectivity and reducing off-target toxicity.

TypeDirect peer
Description

Commercial-stage ADC company with marketed products (Zynlonta) and a pipeline of pyrrolobenzodiazepine-based ADCs. A direct comparable as an ADC-focused oncology company, although more clinically advanced than BioLoomics.

TypeDirect peer
Description

Developer of immune-stimulating ADCs (ISACs) combining tumor-targeting antibodies with immune agonists. Comparable to BioLoomics as a next-generation ADC platform pursuing novel mechanisms to overcome the limitations of traditional ADCs.

5Mythic Therapeutics
TypeDirect peer
Description

Developer of ADCs using a novel conjugation chemistry (FAT-Tag) designed to improve tumor selectivity. Closely comparable to BioLoomics as an early-to-mid-stage ADC-platform company working on differentiated payload-delivery approaches.

TypeDirect peer
Description

ADC and immuno-oncology company building a pipeline of antibody-drug conjugates and immunotherapies. Comparable to BioLoomics as an ADC-focused oncology platform leveraging partnership and licensing strategies.

TypeEmerging player
Description

Developer of ADCs based on the amanitin payload (ATAC platform). Comparable as an emerging ADC-platform company differentiated by payload chemistry, with partnership deals similar to BioLoomics' intended model.

TypeEmerging player
Description

European-based ADC platform company with proprietary conjugation and linker technologies. Comparable to BioLoomics as an early-stage ADC-platform peer focused on improving therapeutic index through novel chemistry.

TypeBroad incumbent
Description

Developer of Enhertu and Datroway in partnership with AstraZeneca. The dominant commercial-stage ADC player; comparable as the benchmark BioLoomics' Super-ADC must outperform on payload delivery and safety profile.

TypeBroad incumbent
Description

Owner of Trodelvy via the Immunomedics acquisition and broader ADC strategy. A large incumbent pursuing ADC innovation in oncology; relevant comparable for understanding competitive dynamics facing BioLoomics.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioLoomics

Biotechnology / Antibody Therapeuticsbioloomics.com

BioLoomics is a Boulder, Colorado preclinical biotechnology company that uses a directed evolution platform in human cells to develop enhanced antibody-drug conjugates (Super-ADCs) for cancer therapeutics, monetizing through co-development partnerships and licensing with large pharmaceutical companies.

BioLoomics firmographics

Firmographics
Name
BioLoomics
Legal name
BioLoomics, Inc.
Website
https://bioloomics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
BioLoomics is a Boulder, Colorado preclinical biotechnology company that uses a directed evolution platform in human cells to develop enhanced antibody-drug conjugates (Super-ADCs) for cancer therapeutics, monetizing through co-development partnerships and licensing with large pharmaceutical companies.
Ownership category
akta.pro rank

BioLoomics industry classification

Industry
Product category
Biotechnology / Antibody Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody drug conjugates
  • Cancer therapeutics development
  • Directed evolution platform
  • Preclinical antibody engineering
  • Oncology biotech research

Where BioLoomics is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioLoomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Co-development Partnerships: BioLoomics plans to form strategic partnerships with large pharmaceutical companies for co-development of Super-ADC therapeutics. Revenue would come from development milestone payments, licensing fees, and potential royalty arrangements.
  2. Pre-clinical Asset Development: Developing pre-clinical assets internally with intent to out-license or partner with pharmaceutical companies for clinical development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

BioLoomics product offering

Product offering

Core offering

BioLoomics develops next-generation antibody-drug conjugates (Super-ADCs) using a proprietary directed evolution platform that engineers antibodies in human cells. The Super-ADCs incorporate oligomerizing membrane binding peptides that enhance tumor cell uptake and payload delivery, addressing the limitation of traditional ADCs that deliver less than 1% of chemotherapy payload to tumors. The company develops pre-clinical assets internally and intends to out-license or co-develop them with large pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

  • Super-ADCs: A proprietary technology platform that enhances antibody-drug conjugates (ADCs) using oligomerizing membrane binding peptides to improve tumor cell uptake and reduce off-target toxicities.

Products and services

  • Super-ADCs (Super Antibody-Drug Conjugates) Next-generation antibody-drug conjugates that incorporate an oligomerizing membrane binding peptide to improve tumor cell uptake. Super-ADCs address the limitation of traditional ADCs that deliver less than 1% of chemotherapy payload to tumors, enhancing payload delivery and reducing off-target toxicities for cancer therapeutics. Targeted at large pharmaceutical companies for co-development partnerships.
  • Directed Evolution Platform A proprietary platform for directed evolution of target degrading antibodies using human cells, enabling the design of antibodies with enhanced functionalities for improved cancer therapeutics. The platform is the technological foundation underlying the company's Super-ADC program and pre-clinical pipeline.
  • Pre-clinical ADC Asset Development Internal development of pre-clinical antibody-drug conjugate assets for cancer therapeutics using BioLoomics' proprietary directed evolution platform. Assets are developed with the intent to out-license or co-develop with pharmaceutical partners for clinical development and commercialization.

Quantifiable outcome

  • Traditional ADCs deliver less than 1% of chemotherapy payload to tumors; Super-ADCs have potential to significantly improve this ratio by enhancing payload delivery through membrane binding peptides

Companies that use BioLoomics

Customer profile

Segments1 record

Ideal customer profiles1 record

BioLoomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

BioLoomics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Large Pharmaceutical CompaniescoreStrategic or Co-development PartnerBioLoomics plans to form strategic partnerships with large pharmaceutical companies to develop pre-clinical assets and advance Super-ADC technology for therapeutic solutions. Partnerships aim to improve therapeutic index of existing assets and enable lower potency payloads in ADC field.

Scale indicators1 record

BioLoomics competitors and assessment

Company assessment

Direct peers

  • Mersana Therapeutics: Clinical-stage ADC developer with proprietary conjugation and payload platforms (e.g., Dolasynthen, Immunosynthen). Directly comparable to BioLoomics as an ADC-platform company pursuing next-generation antibody conjugate technologies for oncology.
  • CytomX Therapeutics: Developer of masked Probody therapeutics that are activated in the tumor microenvironment. Comparable to BioLoomics as a next-generation ADC/antibody platform company improving tumor selectivity and reducing off-target toxicity.
  • ADC Therapeutics: Commercial-stage ADC company with marketed products (Zynlonta) and a pipeline of pyrrolobenzodiazepine-based ADCs. A direct comparable as an ADC-focused oncology company, although more clinically advanced than BioLoomics.
  • Bolt Biotherapeutics: Developer of immune-stimulating ADCs (ISACs) combining tumor-targeting antibodies with immune agonists. Comparable to BioLoomics as a next-generation ADC platform pursuing novel mechanisms to overcome the limitations of traditional ADCs.
  • Mythic Therapeutics: Developer of ADCs using a novel conjugation chemistry (FAT-Tag) designed to improve tumor selectivity. Closely comparable to BioLoomics as an early-to-mid-stage ADC-platform company working on differentiated payload-delivery approaches.
  • Pyxis Oncology: ADC and immuno-oncology company building a pipeline of antibody-drug conjugates and immunotherapies. Comparable to BioLoomics as an ADC-focused oncology platform leveraging partnership and licensing strategies.

Emerging players

  • Heidelberg Pharma: Developer of ADCs based on the amanitin payload (ATAC platform). Comparable as an emerging ADC-platform company differentiated by payload chemistry, with partnership deals similar to BioLoomics' intended model.
  • Tubulis: European-based ADC platform company with proprietary conjugation and linker technologies. Comparable to BioLoomics as an early-stage ADC-platform peer focused on improving therapeutic index through novel chemistry.

Broad incumbents

  • Daiichi Sankyo: Developer of Enhertu and Datroway in partnership with AstraZeneca. The dominant commercial-stage ADC player; comparable as the benchmark BioLoomics' Super-ADC must outperform on payload delivery and safety profile.
  • Gilead Sciences (Kite/Immunomedics): Owner of Trodelvy via the Immunomedics acquisition and broader ADC strategy. A large incumbent pursuing ADC innovation in oncology; relevant comparable for understanding competitive dynamics facing BioLoomics.

Market position

Customer concentration

BioLoomics social profiles

Digital presence

BioLoomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioLoomics leadership team

Management profile

Number of profiles

Profiles3 records

BioLoomics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioLoomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioLoomics

What does BioLoomics do?

BioLoomics develops next-generation antibody-drug conjugates (Super-ADCs) using a proprietary directed evolution platform that engineers antibodies in human cells. The Super-ADCs incorporate oligomerizing membrane binding peptides that enhance tumor cell uptake and payload delivery, addressing the limitation of traditional ADCs that deliver less than 1% of chemotherapy payload to tumors. The company develops pre-clinical assets internally and intends to out-license or co-develop them with large pharmaceutical partners.

Is BioLoomics a public or private company?

BioLoomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioLoomics founded?

BioLoomics was founded in 2019. It employs 1 to 10 people.

Where is BioLoomics based?

BioLoomics is headquartered in Boulder, United States, in the North America region.

How does BioLoomics make money?

Two revenue lines are on record. Co-development Partnerships are the primary driver. The others are pre-clinical Asset Development.

Who are BioLoomics's main competitors?

Direct peers on record are Mersana Therapeutics, CytomX Therapeutics, ADC Therapeutics, Bolt Biotherapeutics, Mythic Therapeutics and Pyxis Oncology. Emerging players are Heidelberg Pharma and Tubulis. Broad incumbents are Daiichi Sankyo and Gilead Sciences (Kite/Immunomedics).

Does BioLoomics have an API?

No public API is recorded for BioLoomics.

What industry is BioLoomics in?

BioLoomics's product category is Biotechnology / Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0BioLoomics: $8.7 Million Raised To Drive Directed Evolution Of Target Degrading Antibodies Using Human CellsBioLoomics has raised $8.7 million in seed financing led by Innovation Endeavors to advance its proprietary platform for the directed evolution of target-degrading antibodies using human cells. The company plans to use the funds to develop pre-clinical assets and form strategic partnerships with large pharmaceutical companies while actively recruiting for CSO and CTO roles. Founder Dr. Douglas Chapnick states that their technology enables testing throughput 10,000 times greater than legacy methods to design safer and more effective cancer therapeutics.FinSMEsBioLoomics Raises $8.7M in Seed FundingBioLoomics, a Boulder-based biotech, raised $8.7M in seed funding led by Innovation Endeavors. The company will use the funds to advance its antibody degrader programs and form strategic partnerships with large pharma companies.Business Wire BlogBioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading AntibodiesBioLoomics raised $8.7 million in seed financing led by Innovation Endeavors to advance its directed evolution platform for antibody degraders. The company will use the funds to develop preclinical assets and form strategic partnerships with large pharma companies.Venture Capital Access OnlineBioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading AntibodiesBioLoomics announced the raising of $8.7 million in seed financing led by Innovation Endeavors to advance its proprietary directed evolution platform for target degrading antibodies. The company intends to use the capital to develop pre-clinical assets and form strategic partnerships with large pharmaceutical companies. This funding brings BioLoomics' total raised capital to $10.1 million as it expands its research capabilities using computer vision-guided robotics.BioSpaceBioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading AntibodiesBioLoomics has raised $8.7 million in seed financing to advance its innovative directed evolution platform for target degrading antibodies. The funding round was led by Innovation Endeavors and includes participation from multiple life science investors. The new capital will support the development of pre-clinical assets and strategic partnerships with large pharmaceutical companies.BizWestBioLoomics raises $8.7M in seed financing – BizWestBioLoomics, a Boulder-based biotechnology startup, has raised $8.7 million in seed financing led by Innovation Endeavors with participation from several other investors. The company plans to use the funds to develop preclinical assets and form strategic partnerships with large pharmaceutical firms.BioloomicsBioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading AntibodiesBioLoomics announced the raising of $8.7 million in seed financing to advance its proprietary platform technology and antibody degrader programs. The round was led by Innovation Endeavors with participation from several other investors, providing capital for pre-clinical asset development and strategic partnerships. This funding supports the company's mission to develop safer, more effective cancer therapeutics using directed evolution of target degrading antibodies.